Learn About Myotonic Dystrophy

What is the definition of Myotonic Dystrophy?

Myotonic dystrophy is part of a group of inherited disorders called muscular dystrophies. It is the most common form of muscular dystrophy that begins in adulthood.

What are the causes of Myotonic Dystrophy?

Myotonic dystrophy type 1 is caused by mutations in the DMPK gene, while type 2 results from mutations in the CNBP gene. The protein produced from the DMPK gene likely plays a role in communication within cells. It appears to be important for the correct functioning of cells in the heart, brain, and skeletal muscles (which are used for movement). The protein produced from the CNBP gene is found primarily in the heart and in skeletal muscles, where it helps regulate the function of other genes.

How prevalent is Myotonic Dystrophy?

Myotonic dystrophy affects at least 1 in 8,000 people worldwide. The prevalence of the two types of myotonic dystrophy varies among different geographic and ethnic populations. In most populations, type 1 appears to be more common than type 2. However, recent studies suggest that type 2 may be as common as type 1 among people in Germany and Finland.

Is Myotonic Dystrophy an inherited disorder?

Both types of myotonic dystrophy are inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one parent with the condition.

Who are the top Myotonic Dystrophy Local Doctors?
Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy

Ambulatory Care Center

417 N. 11th Street, 
Richmond, VA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Nicholas Johnson is a Neurologist in Richmond, Virginia. Dr. Johnson is rated as an Elite provider by MediFind in the treatment of Myotonic Dystrophy. His top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, and Limb-Girdle Muscular Dystrophy. Dr. Johnson is currently accepting new patients.

Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy
Milan, IT 

Giovanni Meola practices in Milan, Italy. Mr. Meola is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy. His top areas of expertise are Myotonic Dystrophy, Myotonic Dystrophy Type 2, Paramyotonia Congenita, Amyotonia Congenita, and Thymectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Myotonic Dystrophy
Elite in Myotonic Dystrophy
6, Dr. Subotic Sr. Street, 11 000, 
Belgrade, SE, RS 

Stojan Peric practices in Belgrade, Serbia. Peric is rated as an Elite expert by MediFind in the treatment of Myotonic Dystrophy. Their top areas of expertise are Paramyotonia Congenita, Myotonic Dystrophy, Myotonic Dystrophy Type 2, and Myasthenia Gravis.

What are the latest Myotonic Dystrophy Clinical Trials?
National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members

Summary: Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their disea...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/Phase 2 Open-label Single Arm Study With Dose Escalation (Part A), and Dose Expansion (Part B) Parts to Evaluate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants 10 to 50 Years Old With Non-congenital Myotonic Dystrophy Type 1

Summary: This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystrophy (DM) type 1 (DM1). The purpose of this study is to evaluate the safety and efficacy of SAR446268 in knocking down dystrophia myotonica protein kinase (DMPK) messenger ribonucleic acid (mRNA) leve...

Who are the sources who wrote this article ?

Published Date: July 01, 2020
Published By: National Institutes of Health